» Factor VIII Inhibitor Reagent Kit (Bethesda Units)

HEMOSTASIS COAGULATION ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA ASSAYS

Factor VIII Inhibitor Reagent Kit (Bethesda Units)

Nijmegen Bethesda Assay

This kit, intended for use in the clinical laboratory, is used to standardize the preparation of samples for the assay of inhibitors by the modified Bethesda Nijmegen method.

Intended for use in the clinical laboratory when performing the modified Bethesda or Besthesda Nijmegen assay.

Access on the manufacturer's website TECHNOCLONE

Reference	4-5152005
Presentation	Kit
Number of assays	2 to 4
Quote

Price list, safety data sheets and notices are accessible to our registered customers.

Reference	Presentation	Number of assays	Quote	Product sheet
4-5152005	Kit	2 to 4

Price list, safety data sheets and notices are accessible to our registered customers.

Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by a Bethesda test and is expressed in BU.
1BU neutralizes 50% of the activity of FVIII for hemophilia A.

- Stability for 1 month after reconstitution

- 2 x 3 mL vials of Factor VIII normal plasma
- 1 vial of 1 mL of Factor VIII inhibitor plasma
- 1 vial of 1 mL of plasma without Factor VIII inhibitor
- 1 vial of Imidazole buffer of 17 mL

Coagulation Reference
DAPTTIN® TC
Factor VIII Deficient Plasma, immunads.
Factor VIII Inhibitor Reagent Kit (Bethesda Units) HCV neg
Solution CaCl₂ 25 mM
TECHNOCHROM® FVIII:C

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

HEMOSTASIS COAGULATION ROUTINE INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA ASSAYS